HomePress-release

Redding, California - June 18, 2024

Monoclonal Antibodies Market to be Worth $449.8 Billion by 2031

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled 'Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User - Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the monoclonal antibodies market is projected to reach $449.8 billion by 2031, at a CAGR of 11.2% from 2024 to 2031. The growth of this market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market’s growth.

Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market’s growth.

Key Players

The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

Monoclonal Antibodies Market: Future Outlook

The monoclonal antibodies market is segmented by Type (Research Monoclonal Antibodies [Research Area {Oncology, Infectious Diseases, Cardiology, Immunology, Neurology, Stem Cell Research, and Other Research Areas}, Application {Proteomics, Drug Discovery and Development, and Genomics}, and Technology {Flow Cytometry, Immunofluorescence, Enzyme-Linked Immunosorbent Assay, Multiplex Immunosorbent Assay, Western Blot, Immunohistochemistry, Immunoprecipitation (IP), Other Research Technologies}], Diagnostic Monoclonal Antibodies [Application {Oncology, Infectious Diseases , Pregnancy Detection/Fertility Testing, Cardiac Marker Testing, and Other Diagnostic Applications} and Technology {ELISA, Lateral Flow Assay, Immunohistochemistry (IHC), Immunoprecipitation (IP), Western Blot (WB), Immunocytochemistry (ICC), and Other Diagnostic Technologies}], and Therapeutic Monoclonal Antibodies [Therapeutic Area {Oncology, Autoimmune Diseases, Neurological Diseases, Infectious Diseases, Other Therapeutic Areas} and Route of Administration {Subcutaneous and Intravenous}]), Production Process (In Vivo Process and In Vitro Process [Upstream Process and Downstream Process]), Source (Human, Humanized, Murine, Chimeric, Other Sources), End User (Pharmaceutical & Biotechnology Companies, Hospitals, Contract Research Organizations, and Other End Users), and Geography. The study also evaluates industry competitors and analyzes the market at the global and regional levels.

Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of 90.2% of the monoclonal antibodies market. This segment’s large market share can be attributed to advancements in discovery and development technologies and increased demand for biosimilars following the expiration of drug patents. Moreover, the increasing demand for targeted cancer therapy, coupled with supportive initiatives for antibody development and approval processes, contributes to the significant market share of this segment.

Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. This segment’s large market share can be attributed to advancements in recombinant technology and the benefits offered by in vitro production processes, such as minimized batch-to-batch variability, scalability, and cost-effectiveness. Moreover, the utilization of in vitro production processes enables the creation of monoclonal antibodies without the need for extensive animal testing, thereby mitigating ethical concerns associated with animal experimentation.

Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of 33.2% of the monoclonal antibodies market. This segment's large market share can be attributed to the advancements in cell culture & biotechnology techniques and the increasing number of drug launches and product approvals for human monoclonal antibodies, which demonstrate high specificity and often do not induce a significant immune response or trigger immune reactions in the body. Additionally, they offer a reduced risk of cross-reactivity and ease of cost-effective large-scale production.

Among the end users covered in this report, in 2024, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. This segment’s large market share can be attributed to the proliferation of public and private hospitals, the increasing prevalence of chronic diseases leading to higher hospital admissions, the rising number of healthcare facilities in emerging economies, and the growing availability of monoclonal antibody therapies in healthcare settings. Additionally, the availability of reimbursement policies for monoclonal antibody treatment at hospitals contributes to the growth of this segment.

Geographic Review

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa.

Among the regions covered in this report, the market in Asia-Pacific is projected to register the highest CAGR of 13.4% during the forecast period. The growth of this regional market is driven by factors such as the rising incidence of diseases, increasing research activities, availability of cost-effective biosimilar options, large population, rising healthcare expenditures, technological advancements, and supportive government initiatives for clinical trials.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5929

Key Questions Answered in the Report:

Which are the high-growth market segments in terms of type, production process, source, end user, and region/country?
What was the historical market size for monoclonal antibodies globally?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, challenges, opportunities, and trends in the monoclonal antibodies market?
Who are the major players in the monoclonal antibodies market?
What is the competitive landscape like?
What are the recent developments in the monoclonal antibodies market?
What are the different strategies adopted by the major players in the monoclonal antibodies market
What are the geographical trends and high growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - June 18, 2024

Monoclonal Antibodies Market to be Worth $449.8 Billion by 2031

Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies